Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

Authors

David N. Franz, Cincinnati Children's Hospital Medical Center
John A. Lawson, Sydney Children's Hospital
Zuhal Yapici, Istanbul University
Christian Brandt, Mara Hospital
Michael H. Kohrman, University of Chicago
Michael Wong, Washington University School of Medicine in St. Louis
Mathieu Milh, Aix‐Marseille University
Adelheid Wiemer-Kruel, Epilepsy Center Kork/TSC Center
Maurizio Voi, Novartis Pharmaceuticals Corporation
Neva Coello, Novartis Pharmaceuticals AG
Wing Cheung, Novartis Pharmaceuticals Corporation
Kai Grosch, Novartis Pharmaceuticals AG
Jacqueline A. French, New York University

Journal

Epilepsia

Publication Date

2018

Volume

59

Issue

6

Inclusive Pages

1188-1197

Document Type

Open Access Publication

DOI

10.1111/epi.14085

Rights and Permissions

Franz, DN, Lawson, JA, Yapici, Z, et al. Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures. Epilepsia. 2018; 59: 1188– 1197. https://doi.org/10.1111/epi.14085 © 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Recommended Citation

Franz, David N.; Lawson, John A.; Yapici, Zuhal; Brandt, Christian; Kohrman, Michael H.; Wong, Michael; Milh, Mathieu; Wiemer-Kruel, Adelheid; Voi, Maurizio; Coello, Neva; Cheung, Wing; Grosch, Kai; and French, Jacqueline A., "Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures." Epilepsia. 59, 6. 1188-1197. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7695